Chromis Therapeutics, Inc. is a San Diego-based biopharmaceutical company, focused on the development of curative treatments for chronic HBV infection, based on its advanced proprietary drug design and discovery platform. The company is seeking investment to advance its novel cccDNA inhibitor (CHR101), viral entry and viral capsid assembly inhibitor lead candidates for the treatment of chronic HBV. CHR101 has the potential to eradicate HBV and to efficiently cure chronically infected HBV patients, as compared to drugs currently on the market. CHR101's activity is supported by a robust discovery preclinical data package.
Company Details
- Address
- 6605 Nancy Ridge Dr., San Diego,ca 92121,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://chromistherapeutics.com
- HQ
- San Diego, CA
Chromis Therapeutics Questions
Chromis Therapeutics's website is http://chromistherapeutics.com
Chromis Therapeutics's LinkedIn profile is https://www.linkedin.com/company/chromis-therapeutics
Chromis Therapeutics's industry is
Biotechnology Research
Chromis Therapeutics's top competitors are
Primmune Therapeutics,
Xcelthera Inc,
Nielsen Biosciences, Inc.,
Inhibrx Biosciences, Inc.,
Metacrine, Inc.,
Qpex Biopharma, Inc.,
Genegocell Inc.,
Lynx Biosciences, Inc.,
Prominex Inc.,
Persimmune.
Chromis Therapeutics's categories are Biotechnology Research
